Physician profile
John Caruso
NPI 1912946617
$15,353.38
in general payments reported to CMS, 2019-2025
45 companies · $2,565 in 2025
The $2,565 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,300 · 2020: $1,983 · 2021: $2,526 · 2022: $1,986 · 2023: $2,164 · 2024: $1,829 · 2025: $2,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,558.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,337.23 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,846.47 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,358.27 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,336.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,123.51 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $754.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $721.02 | 2019-2025 | |
| Amgen INC. | $638.31 | 2019-2024 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $415.85 | 2019-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Dexcom, INC. | $384.70 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $328.37 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.47 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $255.30 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $251.91 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $248.42 | 2022-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Caruso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.